purchase customization

1 Study Coverage
1.1 Neuroendocrine Tumor Drug Product Introduction
1.2 Market by Type
1.2.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 mTOR Protein Inhibitors
1.2.3 Tyrosine Kinase 3 Inhibitors
1.2.4 Somatostatin Receptor Antagonists
1.2.5 Growth Hormone Releasing Factor Antagonists
1.2.6 Somatostatin Receptor Agonists
1.2.7 Others
1.3 Market by Application
1.3.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Neuroendocrine Tumor Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Neuroendocrine Tumor Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Neuroendocrine Tumor Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Neuroendocrine Tumor Drug Sales by Region
2.4.1 Global Neuroendocrine Tumor Drug Sales by Region (2017-2022)
2.4.2 Global Sales Neuroendocrine Tumor Drug by Region (2023-2028)
2.5 Global Neuroendocrine Tumor Drug Revenue by Region
2.5.1 Global Neuroendocrine Tumor Drug Revenue by Region (2017-2022)
2.5.2 Global Neuroendocrine Tumor Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Neuroendocrine Tumor Drug Sales by Manufacturers
3.1.1 Global Top Neuroendocrine Tumor Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neuroendocrine Tumor Drug in 2021
3.2 Global Neuroendocrine Tumor Drug Revenue by Manufacturers
3.2.1 Global Neuroendocrine Tumor Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Drug Revenue in 2021
3.3 Global Neuroendocrine Tumor Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Neuroendocrine Tumor Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Neuroendocrine Tumor Drug Sales by Type
4.1.1 Global Neuroendocrine Tumor Drug Historical Sales by Type (2017-2022)
4.1.2 Global Neuroendocrine Tumor Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)
4.2 Global Neuroendocrine Tumor Drug Revenue by Type
4.2.1 Global Neuroendocrine Tumor Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Neuroendocrine Tumor Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2017-2028)
4.3 Global Neuroendocrine Tumor Drug Price by Type
4.3.1 Global Neuroendocrine Tumor Drug Price by Type (2017-2022)
4.3.2 Global Neuroendocrine Tumor Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Neuroendocrine Tumor Drug Sales by Application
5.1.1 Global Neuroendocrine Tumor Drug Historical Sales by Application (2017-2022)
5.1.2 Global Neuroendocrine Tumor Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)
5.2 Global Neuroendocrine Tumor Drug Revenue by Application
5.2.1 Global Neuroendocrine Tumor Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Neuroendocrine Tumor Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2017-2028)
5.3 Global Neuroendocrine Tumor Drug Price by Application
5.3.1 Global Neuroendocrine Tumor Drug Price by Application (2017-2022)
5.3.2 Global Neuroendocrine Tumor Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Neuroendocrine Tumor Drug Market Size by Type
6.1.1 North America Neuroendocrine Tumor Drug Sales by Type (2017-2028)
6.1.2 North America Neuroendocrine Tumor Drug Revenue by Type (2017-2028)
6.2 North America Neuroendocrine Tumor Drug Market Size by Application
6.2.1 North America Neuroendocrine Tumor Drug Sales by Application (2017-2028)
6.2.2 North America Neuroendocrine Tumor Drug Revenue by Application (2017-2028)
6.3 North America Neuroendocrine Tumor Drug Market Size by Country
6.3.1 North America Neuroendocrine Tumor Drug Sales by Country (2017-2028)
6.3.2 North America Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Neuroendocrine Tumor Drug Market Size by Type
7.1.1 Europe Neuroendocrine Tumor Drug Sales by Type (2017-2028)
7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Type (2017-2028)
7.2 Europe Neuroendocrine Tumor Drug Market Size by Application
7.2.1 Europe Neuroendocrine Tumor Drug Sales by Application (2017-2028)
7.2.2 Europe Neuroendocrine Tumor Drug Revenue by Application (2017-2028)
7.3 Europe Neuroendocrine Tumor Drug Market Size by Country
7.3.1 Europe Neuroendocrine Tumor Drug Sales by Country (2017-2028)
7.3.2 Europe Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Tumor Drug Market Size by Type
8.1.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Neuroendocrine Tumor Drug Market Size by Application
8.2.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Neuroendocrine Tumor Drug Market Size by Region
8.3.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Neuroendocrine Tumor Drug Market Size by Type
9.1.1 Latin America Neuroendocrine Tumor Drug Sales by Type (2017-2028)
9.1.2 Latin America Neuroendocrine Tumor Drug Revenue by Type (2017-2028)
9.2 Latin America Neuroendocrine Tumor Drug Market Size by Application
9.2.1 Latin America Neuroendocrine Tumor Drug Sales by Application (2017-2028)
9.2.2 Latin America Neuroendocrine Tumor Drug Revenue by Application (2017-2028)
9.3 Latin America Neuroendocrine Tumor Drug Market Size by Country
9.3.1 Latin America Neuroendocrine Tumor Drug Sales by Country (2017-2028)
9.3.2 Latin America Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Type
10.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Application
10.2.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country
10.3.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Eisai
11.1.1 Eisai Corporation Information
11.1.2 Eisai Overview
11.1.3 Eisai Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Eisai Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Eisai Recent Developments
11.2 Exelixis, Inc.
11.2.1 Exelixis, Inc. Corporation Information
11.2.2 Exelixis, Inc. Overview
11.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Exelixis, Inc. Recent Developments
11.3 Foresee Pharmaceuticals, LLC
11.3.1 Foresee Pharmaceuticals, LLC Corporation Information
11.3.2 Foresee Pharmaceuticals, LLC Overview
11.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Foresee Pharmaceuticals, LLC Recent Developments
11.4 Hutchison MediPharma Limited
11.4.1 Hutchison MediPharma Limited Corporation Information
11.4.2 Hutchison MediPharma Limited Overview
11.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Hutchison MediPharma Limited Recent Developments
11.5 Intezyne, Inc
11.5.1 Intezyne, Inc Corporation Information
11.5.2 Intezyne, Inc Overview
11.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Intezyne, Inc Recent Developments
11.6 INVENT Pharmaceuticals, Inc.
11.6.1 INVENT Pharmaceuticals, Inc. Corporation Information
11.6.2 INVENT Pharmaceuticals, Inc. Overview
11.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 INVENT Pharmaceuticals, Inc. Recent Developments
11.7 Ipsen S.A.
11.7.1 Ipsen S.A. Corporation Information
11.7.2 Ipsen S.A. Overview
11.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Ipsen S.A. Recent Developments
11.8 Jiangsu Hengrui Medicine Co., Ltd.
11.8.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
11.8.2 Jiangsu Hengrui Medicine Co., Ltd. Overview
11.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
11.9 Karyopharm Therapeutics, Inc.
11.9.1 Karyopharm Therapeutics, Inc. Corporation Information
11.9.2 Karyopharm Therapeutics, Inc. Overview
11.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Karyopharm Therapeutics, Inc. Recent Developments
11.10 Lexicon Pharmaceuticals, Inc.
11.10.1 Lexicon Pharmaceuticals, Inc. Corporation Information
11.10.2 Lexicon Pharmaceuticals, Inc. Overview
11.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Lexicon Pharmaceuticals, Inc. Recent Developments
11.11 Midatech Pharma Plc .
11.11.1 Midatech Pharma Plc . Corporation Information
11.11.2 Midatech Pharma Plc . Overview
11.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Midatech Pharma Plc . Recent Developments
11.12 Millennium Pharmaceuticals, Inc.
11.12.1 Millennium Pharmaceuticals, Inc. Corporation Information
11.12.2 Millennium Pharmaceuticals, Inc. Overview
11.12.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Millennium Pharmaceuticals, Inc. Recent Developments
11.13 MolMed S.p.A.
11.13.1 MolMed S.p.A. Corporation Information
11.13.2 MolMed S.p.A. Overview
11.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 MolMed S.p.A. Recent Developments
11.14 Northwest Biotherapeutics, Inc.
11.14.1 Northwest Biotherapeutics, Inc. Corporation Information
11.14.2 Northwest Biotherapeutics, Inc. Overview
11.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Northwest Biotherapeutics, Inc. Recent Developments
11.15 Novartis AG
11.15.1 Novartis AG Corporation Information
11.15.2 Novartis AG Overview
11.15.3 Novartis AG Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Novartis AG Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Novartis AG Recent Developments
11.16 OctreoPharm Sciences GmbH
11.16.1 OctreoPharm Sciences GmbH Corporation Information
11.16.2 OctreoPharm Sciences GmbH Overview
11.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 OctreoPharm Sciences GmbH Recent Developments
11.17 OXiGENE, Inc.
11.17.1 OXiGENE, Inc. Corporation Information
11.17.2 OXiGENE, Inc. Overview
11.17.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 OXiGENE, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Neuroendocrine Tumor Drug Industry Chain Analysis
12.2 Neuroendocrine Tumor Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neuroendocrine Tumor Drug Production Mode & Process
12.4 Neuroendocrine Tumor Drug Sales and Marketing
12.4.1 Neuroendocrine Tumor Drug Sales Channels
12.4.2 Neuroendocrine Tumor Drug Distributors
12.5 Neuroendocrine Tumor Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Neuroendocrine Tumor Drug Industry Trends
13.2 Neuroendocrine Tumor Drug Market Drivers
13.3 Neuroendocrine Tumor Drug Market Challenges
13.4 Neuroendocrine Tumor Drug Market Restraints
14 Key Findings in The Global Neuroendocrine Tumor Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer